Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...
Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. For its second quarter, Recursion earned $19.2 million in ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Moderna’s move to merge technology and human resources into a single function is the latest sign that artificial intelligence is bringing big changes to the workforce. The biotech company late last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results